NASDAQ:BIAFW bioAffinity Technologies (BIAFW) Stock Price, News & Analysis → Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (From Banyan Hill Publishing) (Ad) Free BIAFW Stock Alerts $0.36 -0.09 (-20.00%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.4750-Day Range$0.12▼$0.7852-Week Range$0.05▼$0.90Volume736 shsAverage Volume4,287 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get bioAffinity Technologies alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About bioAffinity Technologies Stock (NASDAQ:BIAFW)bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.Read More BIAFW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIAFW Stock News HeadlinesApril 2, 2024 | investorplace.comBIAF Stock Earnings: bioAffinity Technologies Reported Results for Q4 2023April 1, 2024 | finance.yahoo.combioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...March 5, 2024 | finance.yahoo.combioAffinity Technologies Reports Accelerating Sales Growth of CyPath® LungDecember 5, 2023 | finance.yahoo.combioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of DirectorsNovember 28, 2023 | finance.yahoo.combioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology PostNovember 16, 2023 | msn.combioAffinity Technologies files for a $25M mixed shelf offeringOctober 10, 2023 | finance.yahoo.combioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth ConferenceApril 29, 2024 | InvestorPlace (Ad)Have You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...September 19, 2023 | finance.yahoo.combioAffinity Technologies Acquires Laboratory Assets of Precision Pathology ServicesSeptember 15, 2023 | wsj.combioAffinity Technologies Inc. WtAugust 14, 2023 | finance.yahoo.combioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 12, 2023 | finance.yahoo.comAMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung CancerJune 15, 2023 | finance.yahoo.combioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics SymposiumMay 22, 2023 | finance.yahoo.combioAffinity Technologies Presents Research Findings at CYTO 2023April 7, 2023 | nasdaq.combioAffinity Technologies, Inc. Rings the Nasdaq Stock Market Closing BellApril 7, 2023 | nasdaq.combioAffinity Technologies, Inc. Rings the Closing BellApril 4, 2023 | bizjournals.comAfter launching IPO, promising SA biotech still chasing profitabilityMarch 24, 2023 | finance.yahoo.combioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023February 13, 2023 | finance.yahoo.combioAffinity Technologies Appoints Julie Anne Overton Director of Corporate CommunicationsJanuary 4, 2023 | marketwatch.comBioAffinity Technologies Shares Rise 8% After Getting Notice to Allow U.S. PatentDecember 1, 2022 | finance.yahoo.combioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO MeetingNovember 14, 2022 | finance.yahoo.combioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.combioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory BoardOctober 25, 2022 | finance.yahoo.combioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and AustraliaOctober 12, 2022 | finance.yahoo.combioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST ConferenceSeptember 28, 2022 | finance.yahoo.combioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6MSee More Headlines Receive BIAFW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNASDAQ:BIAFW CUSIPN/A CIK1712762 Webwww.bioaffinitytech.com Phone210 698 5334FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.53 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Steven Girgenti (Age 78)Founder & Executive Chairman of the Board Comp: $113.75kMs. Maria Zannes J.D. (Age 68)Founder, President, CEO & Director Comp: $299.17kMr. Michael Dougherty CPA (Age 45)M.B.A., VP & CFO Comp: $238.92kMr. Xavier T. Reveles M.S. (Age 54)Chief Operating Officer Dr. Vivienne I. Rebel M.D. (Age 58)Ph.D., Executive VP and Chief Medical & Science Officer Comp: $238.39kMr. Timothy P. Zannes J.D. (Age 71)Executive VP, Secretary & General Counsel Ms. Julie Anne OvertonDirector of CommunicationsMr. Dallas J. ColemanNational Director of SalesDr. William Bauta Ph.D.Senior Vice President of TherapeuticsMore ExecutivesKey CompetitorsPrenetics GlobalNASDAQ:PRENWSeqLLNASDAQ:SQLLWStar EquityNASDAQ:STRRP180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWView All Competitors BIAFW Stock Analysis - Frequently Asked Questions How have BIAFW shares performed in 2024? bioAffinity Technologies' stock was trading at $0.0860 at the start of the year. Since then, BIAFW shares have increased by 318.6% and is now trading at $0.36. View the best growth stocks for 2024 here. Are investors shorting bioAffinity Technologies? bioAffinity Technologies saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 800 shares, a decline of 50.0% from the March 31st total of 1,600 shares. Based on an average trading volume of 3,200 shares, the short-interest ratio is currently 0.3 days. View bioAffinity Technologies' Short Interest. How do I buy shares of bioAffinity Technologies? Shares of BIAFW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIAFW) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
